Search results
G1 Therapeutics discontinue COSELA in TNBC following Phase III flop
Clinical Trials Arena· 5 days agoThe Preserve-2 trial did not meet the primary endpoint of overall survival, with G1 Therapeutics...
The Preserve-2 trial did not meet the primary endpoint of overall survival, with G1 Therapeutics...